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Sexually transmitted viral infections have the potential to be prevented and treated by topical viricides. Here,
Wu et al. (2009) demonstrate that cholesterol-conjugated small interfering RNAs (siRNAs) targeting a cellular
receptor combined with an antiviral siRNA when topically applied to mucosal tissue blocked lethal herpes
virus infections in mice.RNA interference has received a great
deal of attention for its therapeutic poten-
tial (Kim and Rossi, 2007). In particular,
small interfering RNA duplexes (siRNAs),
which mimic the products of the RNase
III enzyme Dicer have been shown to
trigger potent, sequence-specific knock-
down of gene expression in a wide variety
of eukaryotic organisms (Hannon and
Rossi, 2004). These siRNAs are engaged
by Argonaute family members of the
RNA-induced silencing complex (RISC),
where they guide complementary base
pairing with targeted mRNAs, resulting in
cleavage and subsequent destruction of
the targeted transcripts (Hall, 2005; Ham-
mond, 2005). siRNAs can potentially be
used to treat a variety of diseases ranging
from hereditary disorders to viral infec-
tions. A key to successful therapeutic
applications is the ability to deliver these
macromolecules to the tissues of interest.
A number of strategies for systemic
delivery of siRNAs have been described,
but only a small handful is useful for
specific tissue delivery (Kim and Rossi,
2007).
One of the first clinical trials for siRNAs
was directed at inhibition of respiratory
syncytial virus (RSV) in which delivery of
siRNAs was achieved using an unencap-
sulated siRNA in an intranasal spray,
which results in trafficking of the siRNAs
to lung epithelial cells, the site of RSV
infection (DeVincenzo et al., 2008). For
nonrespiratory viral infections the route
of siRNA administration needs to coincide
with the primary sites of viral infection. A
number of viruses are transmitted sexu-
ally via infection of mucosal cells and/or
invading immune cells. These include
serious pathogens such as members of
the herpes virus family, human immuno-
deficiency virus (HIV), and human papil-
oma virus (HPV). The use of topically6 Cell Host & Microbe 5, January 22, 2009 ªapplied viricides is very attractive as either
a prophylaxis or treatment regimen imme-
diately following exposure to the virus.
The first demonstration that topically
applied siRNAs could block a viral infec-
tion came from experiments in mice using
murine herpes simplex virus 2 (HSV2)
infection either preceded by or immedi-
ately followed by vaginal application of
cationic lipid encapsulated siRNAs tar-
geting the viral envelope glycoprotein
UL27 and DNA-binding protein UL29 en-
coding transcripts. Compared with saline
or vehicle controls, the siRNA treatments
resulted in protection of mice from lethal
infection (Palliser et al., 2006). The siRNAs
were most effective when applied either
immediately prior to or within 1 day post
infection, and the protection was quite
transient.
In efforts to improve upon the idea of an
siRNA topical viricide, Wu et al. (2009)
tested another approach, which used
siRNAs conjugated to cholesterol for
topical application. These investigators
first observed that increasing the dosage
of lipoplexed siRNAs did not result in
improved inhibition of HSV2, and in fact
increased amounts of lipid had the nega-
tive side effect of enhancing viral infec-
tivity. This led them to explore other
options for delivery. The choice of choles-
terol was predicated upon earlier studies,
which showed that cholesterol could be
used for functional, systemic delivery of
siRNAs (Soutschek et al., 2004) or anti-
sense oligonucleotide antagonists of
miRNAs (antagomirs) toa varietyof tissues
(Krutzfeldt et al., 2005). Aside fromcholes-
terol, including an siRNA for the cellular
target nectin-1, a receptor required for
HSV2entry, significantly improvedprotec-
tion (Figure1).Knockdownofnectin-1per-
sisted for several days both in vitro and
in vivo following a single administration of2009 Elsevier Inc.the siRNA. A combination of the nectin-1
siRNA along with the antiviral UL29
siRNA gave the most potent and durable
inhibition. Protection from HSV2 induced
lethality was achieved using this combina-
tion of cholesterol-conjugated siRNAs at
a combined dose of 1 mg/kg. The authors
looked for possible non-specific effects
mediated by interferon (IFN) gene induc-
tion, but did not observe any increases
in IFN gene expression relative to the
controls.
Mechanistically, it is of interest to under-
stand how the cholesterol assists in
delivery of siRNAs to mucosal epithelial
cells. Given that cholesterol has been
shown to be a nontoxic and somewhat
general delivery vehicle for oligonucleo-
tides, it is of great interest to better
understand how it facilitates intracellular
delivery of siRNAs. Does cholesterol
dockwith a receptor andbecome internal-
ized, or does it insert within the cell
membrane and become pinocytosed?
How does siRNA with a large cholesterol
moiety enter RISC? Wu et al. (2009)
observed that a single phosphorothioate
(PS) modification on each strand of the
siRNA made a significant difference in the
efficacy of the siRNAs. Is this just a stabi-
lizing property, or does the PS somehow
facilitate the internalization of the siRNAs,
as it does for PS backbone modified
antisense oligonucleotides? Not to be
overlooked, though, is the relatively
high concentration of cholesterol-siRNA
(1 mg/kg) used in these studies to obtain
optimal inhibition. This would translate
into over 100 mg for a single human appli-
cation, so clearly cost will be an issue for
future therapeutic development.
An interesting observation about the
efficacy of siRNAs in the Wu et al. (2009)
study was the discrepancy in the amounts
of intracellular siRNAs targeting UL29
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equal concentrations of material
were applied to the cells and tissue.
The authors observed that the
kinetics of loss of the two siRNAs
was similar, but the amount of
detectable anti-nectin-1 siRNA was
substantially greater than that of
the anti-UL29 siRNA at all times
tested. They point out that this is
probably not an artifact of detection
but could reflect the difference in
stability between an siRNA that is
readily loaded into RISC versus
one that is poorly loaded. Once in
RISC the siRNA would be stabilized,
and its potency could be longer
lasting. If this observation can be
generalized, it could impact on the
cost of treatment if lower concentra-
tions can be effectively used in
topical viricides.
Despite questions about the
mechanism of delivery and the
potential concerns about cost,
the possibility of a topical, vaginally
appliedviricidal treatment for hetero-
sexually transmitted HIV infection is
worth considering. Similar to the
HSV2approach,cotargetingofaviral
and cellular RNA should be considered. In
the case of HIV, there are nowknown to be
several hundred essential cellular genes
required for HIV entry, integration, replica-
tion,maturation, and budding (Brass et al.,
2008; Konig et al., 2008), providing a rich
repository of potential targets for an HIV
viricide. Since HIV infects immune cells, it
will be of interest to determine whether or
not cholesterol-conjugated siRNAs can
be used in a topical viricidal formulation
for prevention of HIV infection.
Overall, the studies of Palliser et al. and
the improvements in delivery described
by Wu et al. provide an exciting opportu-
nity to explore the use of topically applied
siRNAs for treatment of viral infections.
The lack of toxicity and the long lasting
antiviral activity of the combined
cellular and viral targeting by siRNAs
are provocative and clearly warrant
further testing in both animals and
ultimately in human clinical trials.
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Figure 1. Topical siRNA Viricide Mechanism
Cholesterol-conjugated siRNAs dock to mucosal cell surface,
siRNAs are internalized, and antisense guide strand is
engaged in the RNA-induced silencing complex (RISC), which
targets and degrades the viral RNAs and nectin-1 RNA. The
net result of the dual targeting is inhibition of viral infection
and prevention of pathogenicity.Cell Host & Microbe 5, January 22, 2009 ª2009 Elsevier Inc. 7
